Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Tryton's cobalt chromium balloon-expandable coronary stent receives CE Mark

Tryton Medical : 05 February, 2008  (New Product)
Tryton Medical has received CE Mark approval for its Side Branch Stent, which is a high performance cobalt chromium balloon-expandable coronary stent specifically developed for the complete treatment of the entire spectrum of coronary artery bifurcation disease.
Approximately 540,000 annual procedures are performed to address bifurcation lesions, accounting for 20 percent of all coronary lesions treated. With the exception of Tryton's stent, no dedicated solution exists today that fully addresses these lesions.

The results of the Tryton 1 (First-In-Man) Study were presented by Prof Patrick Serruys (Erasmus University/Thoraxcenter, Rotterdam NL) and Ralf Muller, MD (Helios Heart Centrum, Siegburg DE).

When the Tryton cobalt chromium Bare Metal Stent was used with a standard drug eluting Stent (Cypher Select, Taxus or Xience V), no side branch restenosis was observed in the 30 patients treated. The initial core laboratory quantitative analysis reported a late loss of 0.27 +/- 0.42mm in the side branch and 0.12 +/- 0.47mm in the main vessel.

'This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist,' said Professor Patrick W J C Serruys, MD, head of the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.

'CE Mark will allow us to bring this important technology to market in Europe. A market launch is planned for May in conjunction with EuroPCR 2008,' stated H Richard Davis, chief technical officer, Tryton Medical.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo